MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Chembio (CEMI) Receives First Purchase Order For DPP HIV-Syphilis Test 0 comments
    Nov 1, 2013 2:03 PM | about stocks: CEMI

    Point-of-care diagnostic tests leader Chembio Diagnostics announced it has received its first purchase order for the DPP HIV-Syphilis Assay from its Mexican distributor. The DPP HIV-Syphilis Assay is based on Chembio's patented Dual Path Platform (DPP), a POCT platform ideally suited for multiplexing that, in this case, adds a syphilis biomarker to Chembio's DPP HIV 1/2 Test, which has already been approved by the FDA. Adding this biomarker has resulted in a unique finger-stick whole blood test that helps reduce the mother-to-child transmission of both HIV and syphilis. Throughout the world, the incidence of pregnant women being infected with syphilis is higher than for HIV, and prenatal testing is a crucial tool in preventing the transmission of both of these diseases to unborn children.

    The DPP HIV-Syphilis Assay has additionally been approved for inclusion on the U.S. Agency for International Development (USAID) waiver list, which makes the product eligible for procurements by U.S. government-funded global health programs like the President's Emergency Plan for AIDS Relief (PEPFAR) and its associated programs and stakeholders. Receiving USAID approval involves product performance laboratory studies conducted by the International Laboratory Branch of the United States Centers for Disease Control (NASDAQ:CDC) across multiple production lots to verify consistent performance. Chembio expects the results from the CDC's evaluation to be forthcoming. The company is additionally pursuing CE Marking and FDA approval of the DPP HIV-Syphilis Assay.

    The purchase order from Mexico comes on the heels of the favorable evaluation of the sensitivity and specificity of the assay by Mexico's Institute of Epidemiological Diagnosis and Reference (InDRE). The product performed with 100 percent sensitivity and 100 percent specificity on all samples in the InDRE's testing.

    To further product expansion into global markets, Chembio is progressing toward receiving World Health Organization approval for procurement by other large donor-funded global health screening programs. Chembio is additionally working directly in several regions of the world to develop and inform stakeholders about the availability of the DPP HIV-Syphilis Assay.

    For more information, visit chembio.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CEMI
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.